Samsung Bioepis

Overview

Samsung Bioepis Co., Ltd. is a South Korean biopharmaceutical company headquartered in Incheon, South Korea, focused on developing and manufacturing high-quality biosimilars. While primarily known for biosimilars in immunology and oncology, the company has expanded into neuroscience including neurodegenerative diseases.

Company Overview

| Attribute | Value |
|-----------|-------|
| Founded | 2012 |
| Headquarters | Incheon, South Korea |
| Parent | Samsung Biologics (Samsung C&T) |
| Stock | KRX: 321550K |
| CEO | Christopher Hansung Ko |

Neurodegeneration Pipeline

Alzheimer's Disease Programs

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| SB-303 | Anti-[amyloid beta](/proteins/amyloid-beta) biosimilar | Preclinical | Research |
| SB-309 | Anti-[tau](/proteins/tau) antibody biosimilar | Discovery | Early research |

Parkinson's Disease Research

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| SB-401 | [Alpha-synuclein](/proteins/alpha-synuclein) targeting | Discovery | Early research |

Business Model

Samsung Bioepis operates through:

• Biosimilar Development: Developing high-quality biosimilars for global markets
• Contract Manufacturing: Manufacturing biologic drugs for pharmaceutical partners
• Novel Drug Discovery: Expanding into novel drug development for unmet medical needs

Global Partnerships

Overview

Samsung Bioepis Co., Ltd. is a South Korean biopharmaceutical company headquartered in Incheon, South Korea, focused on developing and manufacturing high-quality biosimilars. While primarily known for biosimilars in immunology and oncology, the company has expanded into neuroscience including neurodegenerative diseases.

Company Overview

| Attribute | Value |
|-----------|-------|
| Founded | 2012 |
| Headquarters | Incheon, South Korea |
| Parent | Samsung Biologics (Samsung C&T) |
| Stock | KRX: 321550K |
| CEO | Christopher Hansung Ko |

Neurodegeneration Pipeline

Alzheimer's Disease Programs

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| SB-303 | Anti-[amyloid beta](/proteins/amyloid-beta) biosimilar | Preclinical | Research |
| SB-309 | Anti-[tau](/proteins/tau) antibody biosimilar | Discovery | Early research |

Parkinson's Disease Research

| Drug | Mechanism | Stage | Status |
|------|-----------|-------|--------|
| SB-401 | [Alpha-synuclein](/proteins/alpha-synuclein) targeting | Discovery | Early research |

Business Model

Samsung Bioepis operates through:

• Biosimilar Development: Developing high-quality biosimilars for global markets
• Contract Manufacturing: Manufacturing biologic drugs for pharmaceutical partners
• Novel Drug Discovery: Expanding into novel drug development for unmet medical needs

Global Partnerships

• Bristol Myers Squibb: Partnership for biosimilar development (ended)
• Biogen: Partnership for immunology biosimilars
• Samsung Biologics: Manufacturing infrastructure

Strategic Importance for Neurodegeneration

Samsung Bioepis represents a significant player in making biologic therapies accessible:

Future Pipeline

Samsung Bioepis has announced expansion into neurodegenerative diseases:

| Target | Approach | Timeline |
|--------|----------|----------|
| Alpha-synuclein aggregation inhibitors | Small molecule | 2027 |
| Tau propagation blockers | Antibody therapy | 2028 |
| Neuroinflammation modulators | Biologic | 2028-2029 |

Manufacturing Infrastructure

Samsung Biologics Capabilities

• Total capacity: 620,000 liters (largest in the world)
• Facilities: 4 large-scale manufacturing plants in Incheon
• Inspection track record: First Korean company to receive FDA pre-approval inspection
• EMA certification: Fully compliant with EU manufacturing standards

Quality Systems

• ISO certifications: ISO 9001, ISO 14001, ISO 45001
• GMP compliance: FDA, EMA, PMDA, WHO prequalification
• Continuous verification: Real-time batch monitoring and quality controls

Competitive Position

Biosimilar Market

Samsung Bioepis ranks among the top global biosimilar developers:

| Rank | Company | Market Share |
|------|---------|--------------|
| 1 | Samsung Bioepis | ~30% |
| 2 | Sandoz | ~25% |
| 3 | Mylan/Teva | ~20% |
| 4 | Others | ~25% |

Differentiation Factors

• Manufacturing excellence: State-of-the-art facilities with industry-leading yields
• Speed to market: Accelerated development timelines
• Global reach: Presence in 90+ countries
• Portfolio breadth: 30+ biosimilar programs in development

Financial Performance

• Revenue (2024): ~₩1.5 trillion (~$1.1B)
• R&D investment: ~15% of revenue
• Profitability: Profitable since 2022
• Market cap: ~₩5 trillion (~$3.7B)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References